

Rostislav Åkrabana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1533255/publications.pdf>

Version: 2024-02-01

50
papers

1,557
citations

393982

19
h-index

315357

38
g-index

58
all docs

58
docs citations

58
times ranked

2193
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Neurology</i> , The, 2017, 16, 123-134.	4.9	233
2	Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. <i>FEBS Letters</i> , 2006, 580, 3582-3588.	1.3	211
3	A walk through tau therapeutic strategies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 22.	2.4	211
4	Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 45.	3.0	96
5	A global benchmark study using affinity-based biosensors. <i>Analytical Biochemistry</i> , 2009, 386, 194-216.	1.1	85
6	Intrinsically Disordered Proteins in the Neurodegenerative Processes: Formation of Tau Protein Paired Helical Filaments and Their Analysis. <i>Cellular and Molecular Neurobiology</i> , 2006, 26, 1083-1095.	1.7	61
7	Transition of Tau Protein from Disordered to Misordered in Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 24-27.	0.8	48
8	AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENT. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-7.	1.5	44
9	Novel mutations in TLR genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection. <i>BMC Genetics</i> , 2009, 10, 21.	2.7	43
10	Structure and Functions of Microtubule Associated Proteins Tau and MAP2c: Similarities and Differences. <i>Biomolecules</i> , 2019, 9, 105.	1.8	41
11	N-terminal Truncation of Microtubule Associated Protein Tau Dysregulates its Cellular Localization. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 915-926.	1.2	40
12	Folding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423. <i>FEBS Letters</i> , 2004, 568, 178-182.	1.3	39
13	Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases. <i>Protein Expression and Purification</i> , 2004, 35, 366-372.	0.6	36
14	Hyperphosphorylated Truncated Protein Tau Induces Caspase-3 Independent Apoptosis-Like Pathway in the Alzheimer's Disease Cellular Model. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 161-169.	1.2	35
15	Lactoferrin is a natural inhibitor of plasminogen activation. <i>Journal of Biological Chemistry</i> , 2018, 293, 8600-8613.	1.6	32
16	Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. <i>Acta Neuropathologica Communications</i> , 2019, 7, 129.	2.4	32
17	Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S535-S546.	1.2	29
18	X-ray structure of the PHF core C-terminus: Insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease. <i>FEBS Letters</i> , 2007, 581, 5872-5878.	1.3	22

#	ARTICLE	IF	CITATIONS
19	Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation. <i>Acta Neuropathologica Communications</i> , 2020, 8, 74.	2.4	22
20	MIRRAGGE – Minimum Information Required for Reproducible AGGregation Experiments. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 582488.	1.4	19
21	Mapping the C terminal epitope of the Alzheimer's disease specific antibody MN423. <i>Journal of Immunological Methods</i> , 2002, 262, 205-215.	0.6	17
22	Alzheimer's-disease-associated conformation of intrinsically disordered tau protein studied by intrinsically disordered protein liquid-phase competitive enzyme-linked immunosorbent assay. <i>Analytical Biochemistry</i> , 2006, 359, 230-237.	1.1	14
23	Binding of d-mannose-containing glycoproteins to d-mannose-specific lectins studied by surface plasmon resonance. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2011, 382, 198-202.	2.3	14
24	Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. <i>EBioMedicine</i> , 2022, 76, 103818.	2.7	14
25	Subsite specificity of the proteinase from myeloblastosis associated virus. <i>FEBS Letters</i> , 1991, 282, 73-76.	1.3	13
26	The Structure and Interactions of SpoIIISA and SpoII SB, a Toxin-Antitoxin System in <i>Bacillus subtilis</i> . <i>Journal of Biological Chemistry</i> , 2011, 286, 6808-6819.	1.6	12
27	Monoclonal antibody MN423 as a stable mold facilitates structure determination of disordered tau protein. <i>Journal of Structural Biology</i> , 2010, 171, 74-81.	1.3	11
28	Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody Fab fragments. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2012, 68, 1181-1185.	0.7	10
29	A novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised in human brain. <i>FEBS Letters</i> , 2007, 581, 617-622.	1.3	9
30	NMR Studies of Tau Protein in Tauopathies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 761227.	1.6	9
31	Structure Solution of Misfolded Conformations Adopted by Intrinsically Disordered Alzheimers Tau Protein. <i>Protein and Peptide Letters</i> , 2009, 16, 61-64.	0.4	8
32	Neuronal Expression of Truncated Tau Efficiently Promotes Neurodegeneration in Animal Models: Pitfalls of Toxic Oligomer Analysis. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1017-1025.	1.2	8
33	Preserving free thiols of intrinsically disordered tau protein without the use of a reducing agent. <i>Analytical Biochemistry</i> , 2008, 383, 343-345.	1.1	7
34	Unravelling viral camouflage: approaches to the study and characterization of conformational epitopes. <i>Acta Virologica</i> , 2015, 59, 103-116.	0.3	7
35	Preparation, Crystallization and Preliminary X-Ray Analysis of the Fab Fragment of Monoclonal Antibody MN423, Revealing the Structural Aspects of Alzheimers Paired Helical Filaments. <i>Protein and Peptide Letters</i> , 2006, 13, 941-944.	0.4	6
36	The structure of the unstructured: mosaic of tau protein linear motifs obtained by high-resolution techniques and molecular simulation. <i>General Physiology and Biophysics</i> , 2021, 40, 479-493.	0.4	6

#	ARTICLE	IF	CITATIONS
37	Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide. Bratislava Medical Journal, 2018, 119, 201-204.	0.4	5
38	Non-robotic high-throughput setup for manual assembly of nanolitre vapour-diffusion protein crystallization screens. Journal of Applied Crystallography, 2012, 45, 1061-1065.	1.9	2
39	Crystallization and preliminary X-ray diffraction analysis of two peptides from Alzheimer PHF in complex with the MN423 antibody Fab fragment. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 1186-1190.	0.7	1
40	Structural insights into the conformation of the proline rich region of neuronal protein tau. Acta Crystallographica Section A: Foundations and Advances, 2015, 71, s46-s47.	0.0	1
41	O40406: The First Tau Vaccine for Therapy of Alzheimer's Disease and FTLD: From Tau Structure to Human Clinical Trials. Alzheimer's and Dementia, 2016, 12, P341.	0.4	1
42	Generation, accumulation and degradation of aberrant tau proteins in cortical neurons of transgenic rat during pathogenesis of chronic neurodegenerative disease. FASEB Journal, 2008, 22, 324-324.	0.2	1
43	Interaction kinetics reveal distinct properties of conformational ensembles of three-repeat and four-repeat tau proteins. FEBS Letters, 2022, , .	1.3	1
44	P3-273 Novel anti-tau monoclonal antibody with specificity for NI terminal insert. Neurobiology of Aging, 2004, 25, S432.	1.5	0
45	P3-222 Truncated tau is intimately involved in formation of PHF. Neurobiology of Aging, 2004, 25, S418.	1.5	0
46	Novel mutations in the toll like receptor genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection. Nature Precedings, 2008, , .	0.1	0
47	Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy. Cellular and Molecular Neurobiology, 2022, 42, 125-136.	1.7	0
48	Protein-Engineered Proteinase of Myeloblastosis Associated Virus, An Enzyme of High Activity and HIV-1 Proteinase-Like Specificity. Advances in Experimental Medicine and Biology, 1991, 306, 515-518.	0.8	0
49	The Effects of 1-Propanol on Behaviour of Human Serum Albumin in Alkaline Solution. Collection of Czechoslovak Chemical Communications, 1993, 58, 267-280.	1.0	0
50	Proteomic Approaches for Diagnostics of Canine and Feline Dementia. , 2017, , 113-127.		0